InvestorsHub Logo
Followers 58
Posts 10144
Boards Moderated 1
Alias Born 09/21/2016

Re: georgejjl post# 399199

Friday, 01/20/2023 11:39:16 AM

Friday, January 20, 2023 11:39:16 AM

Post# of 462250

A 27% improvement compared to placebo in the CDR SB score at just 48 weeks for Anavex’s blarcamesine is better than EISAI’s/Biogen’s lecanemab at the same time point.

georgejji

Good observation. Pointing out such trial performance comparisons in a 1:1 ...head : head, fact based manner is helpful and should help to keep investors informed and rational.

CARRY ON.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News